Editor's note

This ExpertREACT article was originally published on 5 August 2010. Financial results and market positions described reflect the state of knowledge at that date.

Q2 revenues decline as H1N1 fades

According to VacZine Analytics' analysis, the major vaccine players sold approximately $4.62bn in Q2 2010, a decline on the Q1 figure of $6.34bn. Most of the decline was attributable to slowing H1N1 pandemic vaccine sales, which still amounted to $708m but were substantially reduced from $2.83bn in Q1. Stripping out H1N1 sales, Q2 2010 was broadly comparable to Q2 2009. In reported dollar terms, GSK was the leading company in Q2 selling approximately $1.395bn (£664m). Cervarix, launched in the US and Japan, had recorded $194m so far in 2010 - despite US sales being only $8m due to delays in VFC (Vaccines For Children) funding. Once this funding stream came online, Cervarix was expected to become a half-billion dollar product. Synflorix had gained approximately 20% market share in Germany and ~70% in Hong Kong, with low pricing seen as GSK's strategy to gain market share over Prevnar/Prevenar.

Sanofi Pasteur moved into second place in dollar terms for Q2 with reported sales of approximately $1,095m (€748m). Paediatric vaccines made up the largest proportion of sales (~37%), with improved performance in Pentaxim (+33.3%) and Pentacel (+8.0%). Sanofi remained heavily focused on seasonal flu with its new ACIP recommendations - which for the first time extended recommendation to everyone over six months and included Fluzone High Dose for the over-65s - expected to drive a record US season.

Q2 2010 H1N1 revenues
$708m
Down sharply from $2.83bn in Q1 2010 as pandemic vaccine demand diminished; top 5 Q2 total was $4.62bn

Menveo approval and meningococcal positioning

Novartis Vaccines had recently gained US and EU approval for its new meningococcal ACWY vaccine Menveo (for individuals over 11 years). VacZine Analytics forecasted less than $50-100m in US revenues for Menveo by year-end, noting that the product alone would not replace lost H1N1 revenue unless it gained infant schedule recommendation. The potential high-revenue generator for Novartis remained the MenB vaccine - still in Phase III and expected to be submitted to European regulators in 2010. GSK had also accumulated a further $400m in H1N1 sales in Q2, bringing its cumulative H1N1 total since 2009 to approximately $3.5bn - evidence of the commercial power of GSK's influenza manufacturing infrastructure built since 2004.